HEPATOPROTECTIVE THERAPY FOR DIFFUSION LIVER DISEASES IN HIV-INFECTED PATIENTS

Abstract

The aim of the study was to evaluate the effectiveness of remaxol long-term use in HIV-infected patients with chronic viral hepatitis. The results of observation and treatment of 46 HIV-infected patients with diffuse liver damage of a viral etiology (chronic hepatitis C and / or B) were analyzed. Patients were divided into two groups, depending on the treatment regimen. 16 patients of the first group were treated with remaxol (intravenous drip 400 ml daily for 12 days, 2-4 times a year at intervals of 3-6 months) and patients of the second group received standard symptomatic therapy. No specific treatment of HIV was carried out before remaxol prescription. The effectiveness of the therapy was evaluated by clinical, biochemical (liver enzymatic activity) and instrumental (elastography including an assessment of fibrosis levels with METAVIR scale). Inclusion of Remaxol in complex therapy of HIV-infected patients with hepatic damage of viral etiology (CHC and / or CHB) stabilized patients’ general condition. It shows hepatoprotective effect, which is manifested by severity of specific symptoms and enzymatic activity decrease, as well as fibrotic changes in liver tissue. To illustrate this, we describe a clinical case of long-term treatment of a patient using remaxol. The revealed positive effect of remaxol on condition of HIV-infected patients with diffuse liver lesions allows to recommend inclusion of the drug in therapy regimens of these patients.